US OptionsDetailed Quotes
AZN241018C79000
- 0.23
- +0.03+15.00%
15min DelayClose Oct 16 16:00 ET
0.38High0.23Low
0.36Open0.20Pre Close39 Volume269 Open Interest79.00Strike Price1.01KTurnover25.54%IV1.17%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.23Extrinsic Value100Contract SizeAmericanOptions Type0.3006Delta0.2744Gamma326.29Leverage Ratio-0.1746Theta0.0009Rho98.08Eff Leverage0.0173Vega
AstraZeneca Stock Discussion
🔸 Chinese Stocks Surge on Return from Holidays as Euphoria Extends. Chinese stocks listed onshore jumped as trading resumed following a week-long holiday, with encouraging home sales and consumption data giving fresh impetus to a rally sparked by Beijing’s stimulus blitz. The benchmark CSI 300 Index and SSEC Index climbed almost 11% in early trading before paring its advance. The measure h...
FDA Approves Osimertinib For Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer After Chemoradiation Therapy; Recommended Dose Is 80mg Daily Until Disease Progression Or Unacceptable Toxicity
The move surpassed Wall Street's expectations. Analysts had generally anticipated a 25 basis point cut, while the futures market had priced in a 61% probability of a 50 basis point cut and a 39% probability of a 25 basis point reduction.
Market Response to First Rate Cut
St...
Gapping up
$Oracle (ORCL.US)$ Shares of Oracle surged over 6.2% as the company increased its revenue forecast for fiscal 2026 and provided strong guidance for the fiscal year 2029.
$Restoration Hardware (RH.US)$ Shares of the home furnishings retailer jumped 18.9% following a robust second quarter. RH reported adjusted earnings per share of $1.69 on revenue of $830 million, surpassing analysts' expectations of $1.56 p...
The upcoming interest rate cuts are poised to benefit the biotech stock industry, setting the stage for strong performance in the coming quarters.
Reasons:
Cheaper Funding: Lower interest rates make it easier for biotech companies to access capital for research and development, accelerating their progress and growth potential.
Attractive Valuations: Biotech stocks are currently trading at attractive levels, offering investors an opportunity to capitalize on the sector's long-term pot...
No comment yet